Inhibitors of human macrophage migration inhibitory factor (MIF) previously reported in the literature have been reexamined by synthesis, assaying for tautomerase activity, and protein crystallography. Substantial inconsistencies between prior and current assay results are noted. They appear to arise from difficulties with the tautomerase substrates, solubility issues, and especially covalent inhibition. Incubation time variation shows that 3, 4, 6, and 9 are covalent or slow-binding inhibitors. Two protein crystal structures are provided; one confirms that the twice-discovered 3 is a covalent inhibitor. Scheme 1. Reported MIF tautomerase inhibitors.
Macrophage migration inhibitory factor (MIF) is a homotrimeric toroidal protein, which has important functions as a cytokine in regulating inflammation, immune response, and aberrant cell growth. 1 Thus, there is much interest in development of therapeutic agents to interfere with the binding of MIF to its signal transduction partners including CD74. MIF also shows enzymatic activity as a keto-enol tautomerase. Though the activity may be vestigial in humans, the existence of the three catalytic sites at the interfaces of the monomer subunits provides an opportunity to discover small-molecule tautomerase inhibitors that may also interfere with the protein-protein interactions featured in MIF signaling. 2 Indeed, this strategy has been widely pursued and is supported by observed correlations between inhibition of tautomerase activity and biological function of MIF. [1] [2] [3] [4] Most MIF tautomerase inhibitors have arisen through screening efforts over the last fifteen years using Ddopachrome methyl ester (DOPA) and p-hydroxyphenyl pyruvic acid (HPP) as substrates. 2 Our laboratory has participated in such activities 4 as well as in de novo design. 5 Two series of compounds that came from the virtual screening also underwent lead optimization. 6, 7 In a recent report, 5 we noted difficulties with the tautomerase assays and sizable variations in reports of inhibitory activity for the reference compounds (R)-ISO-1 (1) and . The present work expands this investigation to include the 11 previously reported MIF tautomerase inhibitors shown in Scheme 1. The compounds have been reassayed and two crystal structures for complexes with MIF are reported.
The HPP tautomerase assay was carried out as described before. 5 DOPA is a less preferable substrate; it is photosensitive, and it yields a shorter linear range for product formation than HPP, 25 vs 175 sec. Inhibitory activity is monitored by measuring formation of the borate complex of the enol product of HPP at 305 nm using a Tecan Infinite F500 plate reader, after a 20-min incubation of the test compounds with MIF. Human MIF was only expressed on two occasions and consistency in activity was demonstrated using control compounds, especially MIF190 (12) and . We report K i values by performing the assay with variation of the inhibitor's concentration for substrate concentrations of 1 and 2.5 mM using 200 nM MIF. Assay of 12 on 17 occasions has yielded 16 K i values between 0.55 and 0.76 µM and one value of 0.85 µM. K i results are much preferred to the more common IC 50 reports that only require use of one substrate concentration. K i is the binding constant for the inhibitor with the protein, while the IC 50 is dependent on the substrate's concentration and Michaelis constant. Specifically, IC 50 = K i ·(1+[S]/K m ), so a K i value should be smaller than an IC 50 . 8 In addition to 1 9,10 and 2, 11 recently reported MIF inhibitors with high potency were considered. 3 (RDR03785) was discovered in two independent highthroughput screens. 12, 13 4 -6 are the three most potent MIF tautomerase inhibitors from the virtual screening effort of Xu et al., 14 while 7 and 8 are the two new compounds reported by Youssef et al. 15 Most of the compounds were purchased from Alfa Aesar (1,2), Santa Cruz Biotechnology (1, 2), Maybridge (3) ChemBridge (4, 6), and Vitas-M Laboratory (5), though 7 and 8 had to be synthesized. We were unable to find a vendor for compounds DP00477 and ML00144 from the paper by Ouertatani-Sakouhi et al. 12 9 -11 were also reinvestigated; they were previously synthesized in our laboratory and assayed by a collaborator. 6, 7 The identities of all assayed compounds were confirmed by NMR and mass spectrometry, and the purity was >95% as judged by HPLC.
The current K i results are compared with the data from the literature in Table 1 . In general, less consistency may be expected for weaker inhibitors than stronger ones, reflecting solubility and aggregation issues as well as spectral interference at higher concentrations. For (R)-ISO-1 (1) the current assay protocol has been executed three times yielding K i values of 21, 24 and 28 µM, while a wide range of IC 50 values is found in the literature. 4, 9, 10, 13, 15 As previously discussed, 5 we also find 2 to be much less active than the original report of an HPP IC 50 of 0.038 µM. 11 The compound has been assayed several times by us with all results in the 13 -22 µM range.
For new results, it should be stated from the outset that we find 3, 4, 6, and 9 to be covalent inhibitors or possibly slow, tight-binding inhibitors. This was established by observing that their activity varied with the incubation time for the inhibitor with MIF prior to addition of HPP (Figure 1 ). 16 The bound/unbound equilibrium is rapidly established for reversible inhibitors, while bond formation is a slower process. The Pro1 nitrogen of MIF with a pK a of 5 -6 is well known to act as the catalytic base for the tautomerase reaction and as a nucleophile forming covalent adducts. 1, 2 We have previously reported crystal structures for two biaryl triazoles including 12 that confirm formation of the expected noncovalent complexes. 5 Consistently, for the closely related 13, there is negligible effect of increasing the incubation time, while for 3, 4, 6, and 9 the initial velocities decrease markedly with increasing time. 4 and 6 both contain an acylthiourea functionality, which is prone to nucleophilic attack and has led to covalent modification of MIF for related compounds. 12, 17 For 3, we also obtained an 1.85-Å x-ray crystal structure clearly showing a covalent bond between Pro1 and the benzylic carbon atom of 3 (r(N-C) = 1.48 Å) with the morpholine ring missing (Figure 2 ). 18 The remaining fragment is oriented with the CF 3 group inward near Asn97; there is a hydrogen bond between the carbonyl group of the fragment and the NH of Ile64, and the benzodioxole ring is π-stacked between Tyr36 and Phe113. Several mechanisms are possible; the simplest is that the morpholine nitrogen is protonated and attack by the Pro1 nitrogen atom displaces neutral morpholine. Alternatively, the phenol assists E1 elimination of the morpholine, and Pro1 adds to the resultant protonated enone. 19 The reactive substructure here is a "phenolic Mannich base", which has been designated as a frequent hitter in assays (PAINS). 20 Additional compounds reported by Zapatero et al. 13 can also be expected to lose morpholine or a piperidine in a similar manner.
The prior claims 12,13 that 3 is a non-covalent inhibitor of MIF are incorrect based on the current evidence. Furthermore, a triply branched compound like 3 cannot be expected to be accommodated in the narrow, tubelike active site of MIF without largescale reorganization. We also attempted to determine structures for complexes of 4 and 6, but we were not able to obtain co-crystals. The aqueous solubilities of several compounds were measured at pH 6.5 with a shake-flask procedure (Table  1) ; 5.21 the very low solubility of 4 (<1 µg/mL; <3 µM) impedes crystallization, and assay uncertainties are also expected. Precipitate was visible in the wells at 20 µM.
With the exception of 9, the rest of the compounds in Table 1 did not show time-dependent assay results. For 5, the present and prior 14 K i values are in acceptable accord near 10 µM, while 8 and especially 7 are found to be much less active than before. 15 We also synthesized the 2-isomer of 7, 14, expecting it to be more active given its more linear shape (Scheme 2). The difference turned out only to be a factor of 2 favoring 14. It was also possible to obtain co-crystals with 14, but not with the less potent 7. The resultant x-ray structure for the complex with MIF ( Figure 3 ) features hydrogen bonds between Pro1 and N1 of 14 (2.38 Å) , and between the meta-hydroxyl group and the CO of Ile64 (2.74 Å), and π-stacking with Phe113.
Investigation of 9 and 10 in the incubation tests showed surprisingly that 9 acts like a covalent or slowbinding inhibitor and 10 does not. Attempts to obtain crystal structures for their complexes were unsuccessful. From the prior modeling, 7 10 is expected to sit farther back in the active site than 9 with likely formation of a hydrogen bond between the hydroxyl group and Asn97 (cf., Figure 1 of ref. 7) . The repositioning of 9 may promote a covalent interaction between the Pro1 nitrogen and carbonyl group of 9. Or, 9 may be a non-covalent inhibitor, but it may also be partially modifying one of the three cysteines of MIF, most likely Cys56, 7 forming a disulfide. 22 Effects of the disulfide formation on the tautomerization rate might be slow to evolve. For 10, the present K i of 9 µM is somewhat higher than the prior IC 50 of 1 µM. K i should roughly equal IC 50 in the former case since [HPP] = 0.15 mM 7 and K m = 2.1 mM. 23 Overall, benzisothiazolones should be avoided as possible PAINS. 20, 22 Finally, 11, which evolved from its des-hydroxy analogue (IC 50 = 0.5 µM), 4 was reported as a 0.01µM tautomerase inhibitor. 6 However, the SAR was irregular and normal dose-response was often lacking (cf., Figure  1 of ref. 6) . Normal dose-response was observed for all compounds in the current study below solubility limits. With the present HPP assay, both 11 and its des-hydroxy progenitor show no inhibitory activity. In a fluorescence polarization assay, there is also no evidence of either compound binding to MIF. 24 Furthermore, in spite of acceptable solubility for 11 (21.9 µg/mL; 86 µM), extensive attempts to obtain co-crystals with MIF only yielded apo protein. Reasons for the discrepancies with the former HPP assay results are not clear, though the present procedure benefits from the 96-well format, plate reader, and K i determination. In a western blot, there was evidence of 11 interfering with MIF signaling and Erk1/2 phosphorylation. 6 The present results conclude that any interference is not initiated by formation of a complex between 11 and MIF.
There is much concern about reproducibility in biomedical science. 25, 26 The present study shows that the problems extend to enzymatic assays. The ramifications are broad including wasted effort with lead optimization and the impossibility of developing accurate scoring functions for virtual screening based on such data. Finding a mix of covalent and non-covalent inhibitors by either HTS or virtual screening is likely commonplace as nucleophilic residues are a standard feature of enzyme active sites and many library compounds have unsaturated functionality prone to addition reactions. For covalent or slow-binding inhibitors, any K i and IC 50 results are incubation time-dependent and are effectively random numbers. Their inclusion in SAR tables is misleading. Even for non-covalent MIF inhibitors there are substantial discrepancies in the assay results from different laboratories. To improve reproducibility, every time an assay is performed, use of established control com-pounds is needed; screening compounds with aqueous solubilities below 10 µM should be avoided; and, hits need to be tested for time-dependent inhibition. For inhibitors of significant interest, report of K i values should be standard and IC 50 s eschewed; this reduces the ambiguities in comparing results from different laboratories and permits confirmation by K d measurements from, e.g., calorimetry or fluorescence polarization.
